Results for this period
First quarter1 January 2026–31 March 2026Non-consolidated (standalone)Japanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
The company recorded business revenue of ¥17,800 thousand from research support payments and other income received periodically under a collaborative drug-discovery research agreement, while incurring business expenses of ¥139,998 thousand, including research and development expenses of ¥67,034 thousand, and recording an impairment loss of ¥135,520 thousand resulting from the impairment of acquired property, plant and equipment.
Not applicable.
| Item | Details |
|---|---|
| Fiscal Period Classification | First quarter |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Non-consolidated (standalone) |
| Period Covered | 1 January 2026–31 March 2026 |
| Net Sales | ¥17 million (YoY -26.2%) |
| Operating profit | ¥-122 million |
| Ordinary income | ¥-120 million |
| Profit attributable to owners of the parent | ¥-256 million |
| Net income per share | -¥39.52 |
| Equity ratio | End of the current fiscal period 85.6 / End of previous period 94.6 |
| Total assets | ¥1,785 million |
| Net assets | ¥1,527 million |
| Full-year earnings forecast | Net Sales ¥113 million (YoY +24.2%) / Operating profit ¥-569 million / Ordinary income ¥-564 million / Net income ¥-567 million |
| Revision to Earnings Forecast | No |
| Annual Dividend Forecast | ¥0.00 → ¥0.00 |
| Segment revenue | not disclosed (omitted because the company has a single segment) |
| Segment profit | not disclosed (omitted because the company has a single segment) |
| Depreciation and amortization | ¥1,772 thousand |
| Impairment loss | ¥135,520 thousand |
| Breakdown of extraordinary income (loss) | Extraordinary income Not disclosed / Extraordinary loss Item Impairment Losses / Amount ¥135,520 thousand |
| Disclosure regarding the going concern assumption | Not applicable. |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | No |
| Issued Shares at Period-End | 6,487,114 shares |
| Treasury Shares at Period-End | — shares |
| Factors Behind Changes in Business Performance | The company recorded business revenue of ¥17,800 thousand from research support payments and other income received periodically under a collaborative drug-discovery research agreement, while incurring business expenses of ¥139,998 thousand, including research and development expenses of ¥67,034 thousand, and recording an impairment loss of ¥135,520 thousand resulting from the impairment of acquired property, plant and equipment. |
Items this document does not state (11)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The company recorded business revenue from research support payments and other income received under a collaborative drug-discovery research agreement, while incurring business expenses, including research and development expenses, and recording an impairment loss resulting from the impairment of acquired property, plant and equipment.